NCT00552565View on ClinicalTrials.gov

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

PHASE3CompletedINTERVENTIONAL
Enrollment

711

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Rezular 15mg

Oral Tablets

DRUG

Placebo

placebo

DRUG

Rezular

Rezular 37.5mg 3xday up to 12 weeks

DRUG

Rezular

Rezular 75mg 3xday up to 12 weeks

Trial Locations (1)

28401

PPD, Wilmington

Sponsors
All Listed Sponsors
lead

AGI Therapeutics, Inc.

OTHER